Dr. Todd Golde is a Professor of Pharmacology and Chemical Biology and Neurology at Emory University. He is the Director of the Emory Center for Neurodegenerative Disease (CND) and associate director of the Emory ADRC. Dr. Golde has made significant contributions to the AD field. His work has provided seminal insights into various aspects of AD pathobiology and therapeutics including the role of Ab42, identification of g-secretase modulators, innate immune activation and targeted immunotherapies. Throughout his career Dr. Golde has emphasized collaborative science and has built and led interdisciplinary teams to address complex questions in neurodegenerative disease.
Jacques P. Tremblay
Université Laval
Canada
Professor Jacques P. Tremblay obtained a PhD in Neurosciences from Univ. of California in San Diego (UCSD) in 1974. He has been working on the development of cell and gene therapies for hereditary diseases since 1987. He has published 322 articles in peer-reviewed journals. He received the Henry Friesen Award from the Royal College of Physicians and Surgeons of Canada. He is currently using the Prime editing technology to correct mutations in the APP, DMD, RYR1, DYSF, MYOC and CFTR genes. He is currently trying to identify the best delivery method (AAVs, EVs, LNPs and VLPs) to deliver the components of the Prime editing technology.
